ENDPOINTS

Biogen gets $250M in Royalty Pharma deal for lupus program

Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced Wednesday. The two have agreed on a deal for litifilimab, an anti-BDCA2 drug currently in ...

Feb 12, 2025 - 12:47
 0
Biogen gets $250M in Royalty Pharma deal for lupus program
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced Wednesday. The two have agreed on a deal for litifilimab, an anti-BDCA2 drug currently in ...
Read More

Tags:

Previous Article

Daily briefing: ‘Devastating’ cuts to NIH grants blocked by legal challenge

Next Article

Russia's War Is Driving Up Emissions by Forcing Planes to Reroute

Related Posts

#ASCOGU: Pfizer’s prostate cancer data leak, show promising results in early-stage study

#ASCOGU: Pfizer’s prostate cancer data leak, show promi...

Feb 11, 2025  0

Travere plans to seek expanded label for kidney drug

Travere plans to seek expanded label for kidney drug

Feb 11, 2025  0

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Inventiva cuts pipeline, lays off nearly entire researc...

Feb 11, 2025  0